Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
ID Serval
serval:BIB_4F4602CBD668
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda
Périodique
Trop Med Int Health
Auteur⸱e⸱s
Mueller Y., Mbulamberi D. B., Odermatt P., Hoffmann A., Loutan L., Chappuis F.
ISSN-L
1360-2276
Statut éditorial
Publié
Date de publication
2009
Volume
14
Numéro
8
Pages
910-7
Langue
anglais
Notes
1365-3156
Mueller, Yolanda
Mbulamberi, Dawson B
Odermatt, Peter
Hoffmann, Axel
Loutan, Louis
Chappuis, Francois
Journal Article
England
Trop Med Int Health. 2009 Aug;14(8):910-7. doi: 10.1111/j.1365-3156.2009.02305.x. Epub 2009 Jun 22.
Résumé
OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Medecins Sans Frontieres in Amudat, eastern Uganda. RESULTS: Between 2000 and 2005, of 3483 clinically suspect patients, 53% were confirmed with primary VL. Sixty-two per cent were children <16 years of age with a male/female ratio of 2.2. The overall case-fatality rate during pentavalent antimonial (n = 1641) or conventional amphotericin B treatment (n = 217) was 3.7%. There was no difference in the case-fatality rate between treatment groups (P > 0.20). The main risk factors for in-hospital death identified by a multivariate analysis were age <6 years and >15 years, concomitant tuberculosis or hepatopathy, and drug-related adverse events. The case-fatality rate among patients >45 years of age was strikingly high (29.0%). CONCLUSION: Subgroups of VL patients at higher risk of death during treatment with drugs currently available in Uganda were identified. Less toxic drugs should be evaluated and used in these patients.
Mots-clé
Adolescent, Adult, Antiprotozoal Agents/administration & dosage/*adverse effects, Child, Child, Preschool, Female, *Hospital Mortality, Humans, Infant, Infant, Newborn, Leishmaniasis, Visceral/drug therapy/*mortality, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, Uganda/epidemiology, Young Adult
Open Access
Oui
Création de la notice
23/02/2016 19:14
Dernière modification de la notice
20/08/2019 15:05
Données d'usage